

## ERIC YAN

Partner  
Fangda Partners

+86 21 2208 1177  
[eric.yan@fangdalaw.com](mailto:eric.yan@fangdalaw.com)



### PRACTICE AREAS

MR. YAN SPECIALIZES IN PRIVATE EQUITY, M&A, FOREIGN DIRECT INVESTMENT AND GENERAL CORPORATE. HE HAS EXTENSIVE EXPERIENCE IN EXECUTING DEALS IN THE HEALTHCARE SECTOR.

### REPRESENTATIVE MATTERS AND CASES

#### Pharmaceutical and Healthcare

##### *Biotech and pharmaceutical*

- Represented **Hillhouse** in its CNY 400 million Series B investment in **Bliss Biopharmaceutical (Hangzhou)**, a biomedical R&D enterprise with independent intellectual property rights, focusing on the R&D and industrialization of anti-tumor biological drugs
- Represented **Hillhouse** in its CNY 1 billion Series C investment in **DAC Biotech**, a high-tech company focusing on the development and clinical trial of antibody-drug conjugates (ADC)
- Represented **Hillhouse** on its co-led USD 145 million Series B investment in **Zhaoke Ophthalmology Pharmaceutical**, an indirect subsidiary of Hong Kong-listed Lee's Pharmaceutical Holdings Limited
- Represented **Hillhouse** in its USD 255 million Series C investment in **InSilico Medicine Cayman Topco**, which provides AI solutions to top biotech companies to enable streamlined R&D to accelerate drug discovery and development
- Represented **Hillhouse** and **Hankang Capital** in their investment in a biotech company that focuses on researching and developing first-in-class drugs
- Represented **Yunfeng** and other investors and CBMG Group management team in the USD 410 million taking-private transaction of CBMG Group

- Represented **Yunfeng** in its minority investment in a company mainly engaged in the elementary research of stem cell technology and the study of relevant clinical data
- Represented **Yunfeng** in its minority investment in a leading contract research organization in Hangzhou, which mainly engages in R&D and MAH for drug products
- Represented **Yunfeng Financial** in its investment in a biotech company in Korea and in its collaboration with that company with respect to the license-in arrangement for certain key pipelines
- Represented **Lilly Asia Ventures** in its lead investment in the Series A financing of **Innostellar Biotherapeutics**, which focuses on gene therapy for innovative drug discovery and manufacture
- Represented **Loyal Valley Capital** in its CNY 450 million Series C investment in **SCIWIND**, a biotech company that focuses on the R&D of innovative therapies for chronic metabolic disease
- Represented **Wuxi AstraZeneca CICC Venture Capital Partnership** in its minority investment in **CBMG Group**
- Represented **CICC** in its investment in a Shanghai company focusing on new drug R&D

*Medical services and other related areas*

- Represented **Swire** in its strategic investment in a high-end private hospital group in Shenzhen under the **UFH brand** (a full-service hospital)
- Represented **Swire** in its strategic investment in **DeltaHealth Group**, which operates a high-end private hospital in Shanghai specializing in cardiovascular diseases
- Represented **Parkway Health**, a leading healthcare services provider in Asia, in its investments in several private hospitals and clinics in various provinces in China
- Represented a buyers group led by the founder of iKang Healthcare Group in their taking-private of **iKang Healthcare Group**
- Represented **Alibaba** in its proposed acquisition of a specialized hospital in Hangzhou
- Represented **Wuxi AppTec** in forming a joint venture with **Mayo Clinic** regarding advanced medical examination technologies
- Represented **Yunfeng** in its exit from a private hospital group in Shanghai
- Represented **Olympus Capital Asia** in its USD 40.2 million mezzanine investment in Tian Jian Hua Xia Medical Group Holdings

- Represented **NewQuest** in its investments in the secondary market, including an obstetrics and gynecology hospital group
- Represented Aisa-Pacific Innovation Center of **Johnson & Johnson** in its early-stage transactions and collaboration projects, including research collaborations, material transfers, and technology licenses
- Represented **Johnson & Johnson** in its establishment of **JLABS @Shanghai**, a world-class incubator for start-ups in the healthcare industry in Shanghai, and now advising JLABS @ Shanghai on its general corporate matters
- Represented **Alibaba** in its proposed acquisition of an online medical consultation service platform
- Represented **Hillhouse** in its minority investment in **Shanghai Zhizhong Medical Technology**, a company focusing on chronic disease management and providing innovative solutions for chronic disease patients, e.g., metabolic disease and cardiovascular disease patients

*Medical devices*

- Represented an investor consortium led by **China Life Private Equity** in a USD 500 million Series A financing of **Shanghai United Imaging Healthcare**, a high-tech unicorn engaging in the design and manufacture of high-end medical imaging devices and the provision of innovative medical information solutions
- Represented **Boyu Capital** in its investment in **Shanghai Gamma Star Medical Science and Technology**, a company engaging in the design and manufacture of medical devices and the operation of cancer treatment centers
- Represented **Hillhouse** in its acquisition of a medical device group engaging in the manufacture and sale of OK lenses
- Representing **TPG** in its proposed investment in a medical device company in Suzhou, which engages in the production and distribution of high-end medical devices treating structural heart disease and cerebrovascular disease
- Represented **Yunfeng** in its investment in a neurological and interventional medical device enterprise

Other Deal

- Represented a consortium of investors led by **Standard Chartered Private Equity** in: (i) their USD 200 million leveraged buyout and related acquisition financing of Siyanli, a high-end beauty service enterprise; (ii) their trade sale of majority interests in Siyanli to a group of private equity investors; and (iii)

their trade sale to a private equity buyer

- Represented **Swire Beverage**, a subsidiary of Swire Pacific (HKSE: 00019), in: (i) its acquisition of equity interests in bottling operations from **The Coca-Cola Company**; (ii) its acquisition through auction of equity interests in bottling operations from **COFCO Coca-Cola Beverages Limited**; and (iii) its disposal of equity interests in bottling operations to COFCO
- Represented **Swire Beverage** in its acquisition of various PRC manufacturing plants from **CCBMH**, a still beverages packaging business, and participated in the restructuring of CCBMH, with six still beverages packaging subsidiaries in the PRC valued at CNY 2 billion being transferred to Swire Beverage
- Represented **China Lodging Group** in its CNY 3.65 billion acquisition of Crystal Orange Hotel
- Represented **Swire** in its sale of cold-chain logistics assets to Vanke
- Represented A-share-listed **Tianjin Tianhai Investment** in its USD 6 billion acquisition of NYSE-listed **Ingram Micro**
- Represented **Jin Jiang International** in its EUR 1.2 billion in acquisitions of **Groupe du Louvre** from Starwood Capital
- Represented **Shanghai Electric Group** in its equity investment in an Italian enterprise in the gas turbine industry and in the establishment of a joint venture in China
- Represented **Alibaba** in its equity investment in **Suning**
- Represented **Hillhouse** in its CNY 800 million investment in the Series C round financing of **Gaodun Education**
- Represented **Alibaba** in its establishment of a joint venture with **Mengniu** to form a business engaging in OTO dairy product services
- Represented **Cainiao Logistics** in its proposed restructuring
- Advising **Local Services Group**, **Starbucks Group**, **Unilever Group**, **Suzano Group** and other well-known domestic and multinational companies on their general corporate matters

## OTHER INFORMATION

### Education

- The University of Hong Kong, J.D. (2013)
- Fudan University, School of Law, LL.B. (2011)

### Professional Qualification

- Admitted to practice in the PRC

### **Professional Background**

Mr. Yan joined the firm in 2013.